Study Evaluating a Gene Therapy for IPEX Syndrome Through the Expression of FOXP3 on Deficient T Cells to Produce Tregs-like.

Phase 2Not Yet RecruitingNCT07697118

Assistance Publique - Hôpitaux de Paris5 enrolled

Overview

The purpose of this study is to evaluate the safety and efficacy of FOXP3-T4 (an autologous gene therapy) alone or in combination with low-dose IL-2 for the treatment of IPEX syndrome. The therapy involves the transplantation of autologous CD4+ T-cells transduced ex vivo with the LV-EF1a-FOXP3-LNGFR lentiviral vector. The study follows a staggered approach: the first two patients will receive FOXP3-T4 monotherapy. Subsequent patients will receive FOXP3-T4 followed if needed by low-dose IL-2 treatment consisting of a daily dose for 5 days, then weekly administrations for 3 months. The study aims to stabilize autoimmune manifestations and potentially cure the underlying disease, ultimately allowing for the discontinuation of ongoing immunosuppressive treatments.

IPEX syndrome is a primary immunodeficiency caused by hemizygous mutations in the gene FOXP3, which encodes an essential transcription factor required to maintain immunological tolerance by thymus-derived regulatory T (Treg) cells. The most common presentation suggestive of the diagnosis of IPEX syndrome is the classical triad of enteropathy, type I diabetes (TID), and eczema in neonatal onset. Still, it is now well established that IPEX syndrome comprises a broad spectrum of clinical manifestations with different degrees of severity and evolution. Currently, the only curative treatment for the severe form is allogeneic hematopoietic stem cell transplantation (HSCT). However, because of its significant toxicity, it can be proposed only for more severe presentations and when an HLA identical donor is available. Moreover, the post-HSCT prognosis is also linked to prior disease activity and organ failures. This clinical study aims to assess a new therapeutical strategy consisting of the conversion of the IPEX patient's CD4+T-cells into functional Treg-like cells by transducing them with an optimized bidirectional lentivirus vector expressing human FOXP3 and a truncated form of the low-affinity nerve growth factor receptor (ΔLNGFR) allowing the selection of the transduced cells. To favour Treg-like cells engraftment and expansion, the FOXP3-T4 infusion may be combined with subcutaneous injection of low-dose IL-2, if needed. Injecting FOXP3-T4 T-reg-like cells into IPEX patients is expected to stably improve the autoimmune manifestations and even cure the underlying disease, allowing the ongoing immunosuppressive treatments to be stopped.

Study Type

INTERVENTIONAL

Allocation

Interventions

FOXP3-T4 drug productGENETIC

Each patient will receive a single IV infusion of FOXP3-T4, autologous gene-modified CD4+ T-transduced ex vivo with a self-inactivating lentiviral vector (LV-EF1a.FOXP3-LNGFR)

ILT-101DRUG

The first two patients included in the study will not receive IL-2 treatment. The others will receive the first injection the FOXP3-T4 treatment and if needed IL2-treatment. For IL2 treatment, patients will receive a daily dose for 5 days, followed by an administration per week for 3 months (ILT-101)

Eligibility

Sex: MALEMin age: 1 YearMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Male patients only * Patients aged from 1 - 45 years of age (the first three patients will be aged between 10 - 45 years of age) * Patient with IPEX syndrome caused by mutation of the FOXP3 gene * Patients are eligible from the second line of treatment onward, even those under controlled disease * Patient with recurrent IPEX symptoms, under immune suppressive medications * Patient for whom HSCT is not feasible or when no suitable compatible donor is available * Patients who have had prior allogeneic blood stem cell transplantation (HSCT) with engraftment failure defined as no intake of donor cells * Patient or parental, guardian's patient signed informed consent * Male participants of reproductive potential with a partner of childbearing potential (WOCBP): willing to use an effective method of contraception during the trial and for at least 12 months post-infusion * Affiliation to a French or European social security scheme Exclusion Criteria: * Unwillingness to return for follow-up during the 2-year study and during the 15 years of long term follow up study. * Patient with short life expectancy * Patient on AME (state medical aid) (unless exemption from affiliation). * Diagnosis of a significant psychiatric disorder of the patient that could seriously impede the ability to participate in the study. * Eligible for an HLA matched sibling or matched unrelated donor blood stem cell transplant (HLA 10/10) and be willing to undergo transplant. * Patients with uncontrolled or ongoing active infections. * HIV-1 or 2 or HTLV-1 infections. * Patients with severe IPEX clinical presentation needing a rapid allogeneic HSCT treatment within 3 months. * Patients with known history of hypersensitivity to IL-2 or any component of the formulation (mannitol, sodium lauryl sulfate, monosodium phosphate dehydrate, disodium phosphate dehydrate, glucose.

Outcomes

Primary Outcomes

Frequency of clinical AEs and pathological variations of laboratory parameters

Number of clinical AEs

Time frame: Up to 24 months post-infusion

Severity of clinical AEs and pathological variations of laboratory parameters

Grading will be performed according to the CTCAE (Common Terminology Criteria for Adverse Events) current version. Severity is rated on a scale of Grade 1 (Mild) to Grade 5 (Death).

Time frame: Up to 24 months post-infusion

Incidence of clinically detectable lymphoproliferation and abnormal clonal dominance

This is measured via Vector Insertion Site Analysis (VISA)

Time frame: Up to 24 months post-infusion

Incidence of clinically detectable lymphoproliferation and abnormal clonal dominance

This is measured by proliferation of LNGFR+ cells

Time frame: Beyond 3 months to 24 months post-infusion

Detection of Replication-Competent Lentivirus (RCL)

Time frame: Up to 24 months post-infusion

Persistence of recirculating LNGFR+among CD4+ T cells

Percentage of LNGFR+ among CD4+ T cells

Time frame: at 3 months post-infusion

Secondary Outcomes

Persistence of FOXP3-T4 Cells

Persistence of recirculating LNGFR among CD4+ T cells

Time frame: Up to 24 months post-infusion

Phenotyping

Deeper phenotyping of FOXP3-T4 (CD4+LNGFR+ CD25+ FOXP3+ CD127low)

Time frame: Up to 24 months post-infusion

Vector Copy Number (VCN) Analysis

Quantification of the transgene copy number (VCN) on drug product and on sorted T-CD4+

Time frame: Up to 24 months post-infusion

Immunophenotyping T and B cells if no change is detected from the baseline (e.g. before treatment), the immunological phenotype

Time frame: Beyond 3 months to 24 months post-infusion

TCR repertoire

Evaluated by NGS before and after the treatment with FOXP3-T4

Time frame: At 3 months, 12 months and 24 months, post-infusion

Autoantibodies dosage

Time frame: At 3 months, 6 months, 12 months and 24 months post-infusion

Organ-Specific Remission: Skin disease

Diminution of the skin lesions severity

Time frame: Up to 24 months post-infusion

Organ-Specific Remission: Skin disease

Diminution of inflammation in the skin biopsy

Time frame: Up to 24 months post-infusion

Organ-Specific Remission: Endocrine System Function

Evaluation of the functions of endocrine glands

Time frame: Up to 24 months post-infusion

Organ-Specific Remission: Endocrine System Function

Reduction of insulin dose administrered

Time frame: Up to 24 months post-infusion

Organ-Specific Remission: Endocrine System Function

Reduction of HBA1C

Time frame: Up to 24 months post-infusion

Organ-Specific Remission: Renal function

Improvement of creatine and creatine clearance